Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 10/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831691 | 0.96 | HCAR2 (0.45) | HCAR2CDK2CCNA2CCNA1HCAR3 | |
| SCHEMBL17565544 | 0.95 | HCAR2 (0.44) | HCAR2CDK2CCNA2CCNA1HCAR3 | |
| SCHEMBL12505818 | 0.92 | HCAR2 (0.46) | HCAR2CDK2CCNA2CCNA1HCAR3 | |
| SCHEMBL31466557 | 0.86 | MKNK1 (0.49) | HCAR2CDK2CCNA2CCNA1IGF1R | |
| SCHEMBL23103095 | 0.84 | DAO (0.44) | HCAR2CDK2CCNA2CCNA1HCAR3 | |
| SCHEMBL14925555 | 0.80 | CCNT1 (0.35) | HCAR2CDK2CCNA2CCNA1IGF1R | |
| SCHEMBL22815463 | 0.80 | HCAR2 (0.41) | HCAR2CDK2CCNA2CCNA1HCAR3 | |
| SCHEMBL22643866 | 0.76 | JAK2 (0.38) | HCAR2CDK9CCNT1DAOL3MBTL1 | |
| SCHEMBL26549015 | 0.75 | IGF1R (0.52) | HCAR2CDK2CCNA2CCNA1IGF1R | |
| SCHEMBL17412844 | 0.75 | HCAR2 (0.53) | HCAR2CDK2CCNA2CCNA1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783531-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783531-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311813-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311813-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, TYRO3, BTK | HCAR2 1356/4885CDK2 311/4885CCNA2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.